| 臺大學術典藏 |
2022-01-24T09:31:35Z |
Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition
|
Su T.-H.; Shiau C.-W.; Jao P.; Liu C.-H.; CHUN-JEN LIU; Tai W.-T.; Jeng Y.-M.; Yang H.-C.; Tseng T.-C.; Huang H.-P.; Cheng H.-R.; Chen P.-J.; Chen K.-F.; Kao J.-H.; Chen D.-S. |
| 臺大學術典藏 |
2022-01-24T09:31:33Z |
Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers
|
Tseng T.-C.; CHUN-JEN LIU; Yang H.-C.; Chen C.-L.; Yang W.-T.; Tsai C.-S.; Kuo S.F.-T.; Verbree F.C.; Su T.-H.; Wang C.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:30Z |
Hepatitis C viral infection increases the risk of lymphoid-neoplasms: A population-based cohort study
|
Su T.-H.; CHUN-JEN LIU; Tseng T.-C.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Wu S.-J.; Chen P.-J.; Chen D.-S.; Chen C.-L.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:30Z |
Hepatitis B surface antigen loss and hepatocellular carcinoma development in patients with dual hepatitis B and C infection
|
Yang W.-T.; Wu L.-W.; Tseng T.-C.; Chen C.-L.; Yang H.-C.; Su T.-H.; Wang C.-C.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; CHUN-JEN LIU; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:30Z |
Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis
|
Yang H.-I.; Tseng T.-C.; Liu J.; Lee M.-H.; CHUN-JEN LIU; Su T.-H.; Batrla-Utermann R.; Chan H.L.Y.; Kao J.-H.; Chen C.-J. |
| 臺大學術典藏 |
2022-01-24T09:31:29Z |
Perspectives on dual hepatitis B and C infection in Taiwan
|
CHUN-JEN LIU; Chen P.-J.; Chen D.-S.; Tseng T.-C.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:27Z |
Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C
|
Mah Y.-H.; Liu C.-H.; Chen C.-L.; Tseng T.-C.; CHUN-JEN LIU; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:25Z |
Impact of occult hepatitis B on the clinical outcomes of patients with chronic hepatitis C virus infection: A 10-year follow-up
|
Chen H.-Y.; Su T.-H.; Tseng T.-C.; Yang W.-T.; Chen T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H.; CHUN-JEN LIU |
| 臺大學術典藏 |
2022-01-24T09:31:24Z |
Fibrosis-4 Index Helps Identify HBV Carriers with the Lowest Risk of Hepatocellular Carcinoma
|
Tseng T.-C.; CHUN-JEN LIU; Su T.-H.; Yang W.-T.; Chen C.-L.; Yang H.-C.; Wang C.-C.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:23Z |
Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis
|
Su T.-H.; Shiau C.-W.; Jao P.; Yang N.-J.; Tai W.-T.; CHUN-JEN LIU; Tseng T.-C.; Yang H.-C.; Liu C.-H.; Huang K.-W.; Hu T.-C.; Huang Y.-J.; Wu Y.-M.; Chen L.-J.; Chen P.-J.; Chen D.-S.; Chen K.-F.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:21Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
Liu C.-H.; CHUN-JEN LIU; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:20Z |
Distinct Relapse Rates and Risk Predictors after Discontinuing Tenofovir and Entecavir Therapy
|
Su T.-H.; Yang H.-C.; Tseng T.-C.; Liou J.-M.; Liu C.-H.; Chen C.-L.; Chen P.-J.; Chen D.-S.; CHUN-JEN LIU; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:19Z |
Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection
|
Liu C.-H.; Sun H.-Y.; CHUN-JEN LIU; Sheng W.-H.; Hsieh S.-M.; Lo Y.-C.; Liu W.-C.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:19Z |
Fibrosis-4 index predicts cirrhosis risk and liver-related mortality in 2075 patients with chronic HBV infection
|
Tseng T.-C.; CHUN-JEN LIU; Su T.-H.; Yang W.-T.; Chen C.-L.; Yang H.-C.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:18Z |
Acoustic radiation force impulse US imaging: Liver stiffness in patients with chronic hepatitis B with and without antiviral therapy
|
Su T.-H.; Liao C.-H.; Liu C.-H.; Huang K.-W.; Tseng T.-C.; Yang H.-C.; CHUN-JEN LIU; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:18Z |
Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study
|
Liu C.-H.; Huang Y.-J.; Yang S.-S.; Chang C.-H.; Yang S.-S.; Sun H.-Y.; CHUN-JEN LIU; Liu W.-C.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:17Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
Liu C.-H.; CHUN-JEN LIU; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:17Z |
Profile and value of FIB-4 in patients with dual chronic hepatitis C and B
|
CHUN-JEN LIU; Tseng T.-C.; Yang W.-T.; Su T.-H.; Yang H.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:16Z |
Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin's lymphoma and multiple myeloma
|
Su T.-H.; CHUN-JEN LIU; Tseng T.-C.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Wu S.-J.; Chen P.-J.; Chen D.-S.; Chen C.-L.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:16Z |
Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection
|
Su T.-H.; CHUN-JEN LIU; Tseng T.-C.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Wu S.-J.; Chen P.-J.; Chen D.-S.; Chen C.-L.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:14Z |
A simple non-invasive test for ruling out cirrhosis in chronic hepatitis B
|
Tseng T.-C.; Shih Y.-F.; CHUN-JEN LIU |
| 臺大學術典藏 |
2022-01-24T09:31:13Z |
Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection
|
Liu C.-H.; Su T.-H.; CHUN-JEN LIU; Hong C.-M.; Yang H.-C.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:12Z |
NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging
|
Su T.-H.; Liao S.-H.; Hong C.-M.; CHUN-JEN LIU; Tseng T.-C.; Liu C.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chen C.-L.; Adhoute X.; Bourli?re M.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:12Z |
High Level of Hepatitis B Core–Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load
|
Tseng T.-C.; CHUN-JEN LIU; Hsu C.-Y.; Hong C.-M.; Su T.-H.; Yang W.-T.; Chen C.-L.; Yang H.-C.; Huang Y.-T.; Fang-Tzu Kuo S.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:12Z |
Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism
|
Su T.-H.; Yang H.-C.; Tseng T.-C.; Chou S.-W.; Lin C.-H.; Liu C.-H.; CHUN-JEN LIU; Chen C.-L.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:11Z |
Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis
|
Su T.-H.; Peng C.-Y.; Tseng T.-C.; Yang H.-C.; CHUN-JEN LIU; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:10Z |
Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy
|
Tseng T.-C.; Peng C.-Y.; Hsu Y.-C.; Su T.-H.; Wang C.-C.; CHUN-JEN LIU; Yang H.-C.; Yang W.-T.; Lin C.-H.; Yu M.-L.; Lai H.-C.; Tanaka Y.; Nguyen M.H.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:10Z |
Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals
|
Liu C.-H.; Lee M.-H.; Lin J.-W.; CHUN-JEN LIU; Su T.-H.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:10Z |
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan
|
Liu C.-H.; CHUN-JEN LIU; Hung C.-C.; Hsieh S.-M.; Su T.-H.; Sun H.-Y.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:09Z |
HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis
|
Tseng T.-C.; CHUN-JEN LIU; Chang C.T.; Su T.-H.; Yang W.-T.; Tsai C.-H.; Chen C.-L.; Yang H.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:09Z |
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment
|
Liu C.-H.; Yang S.-S.; Peng C.-Y.; Lin W.-T.; CHUN-JEN LIU; Su T.-H.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:06Z |
Antiviral therapy against chronic hepatitis C is associated with a reduced risk of oral cancer
|
Su T.-H.; Tseng T.-C.; CHUN-JEN LIU; Chou S.-W.; Liu C.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chen C.-L.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:05Z |
Pathologic findings of patients with nonalcoholic fatty liver disease and the impact of concurrent hepatitis B virus infection in Taiwan
|
Su H.-J.; Kao J.-H.; Tseng T.-C.; Yang H.-C.; Su T.-H.; Chen P.-J.; CHUN-JEN LIU |
| 臺大學術典藏 |
2022-01-24T09:31:03Z |
High risk of clinical relapse in patients with chronic Hepatitis B virus infection after cessation of prophylactic antiviral therapy for rituximab-containing chemotherapy
|
Chang W.-Y.; Chiu Y.-C.; Chiu F.-W.; Hsu Y.-C.; Tseng T.-C.; Cheng P.-N.; Yang S.-S.; CHUN-JEN LIU; Su T.-H.; Yang H.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:02Z |
Clinical and histologic features of patients with biopsy-proven metabolic dysfunction-associated fatty liver disease
|
Huang S.-C.; Su H.-J.; Kao J.-H.; Tseng T.-C.; Yang H.-C.; Su T.-H.; Chen P.-J.; CHUN-JEN LIU |
| 臺大學術典藏 |
2022-01-24T09:31:01Z |
Serum cytokine/chemokine profiles predict hepatitis B reactivation in HBV/HCV co-infected subjects receiving direct-acting antiviral agents
|
Huang S.-C.; Cheng P.-N.; Liu C.-H.; Yang H.-C.; Su T.-H.; Tseng T.-C.; Chen P.-J.; Kao J.-H.; CHUN-JEN LIU |
| 臺大學術典藏 |
2022-01-24T09:31:01Z |
Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis
|
Su T.-H.; Peng C.-Y.; Chang S.-H.; Tseng T.-C.; CHUN-JEN LIU; Chen C.-L.; Liu C.-H.; Yang H.-C.; Chen P.-J.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:00Z |
Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment
|
Liu C.-H.; Peng C.-Y.; Kao W.-Y.; Yang S.-S.; Shih Y.-L.; Lin C.-L.; Tsai M.-K.; Lee C.-Y.; Chang C.-C.; Wu J.-H.; CHUN-JEN LIU; Su T.-H.; Tseng T.-C.; Chen P.-J.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:30:58Z |
Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load
|
Tseng T.-C.; CHUN-JEN LIU; Yang W.-T.; Hsu C.-Y.; Hong C.-M.; Su T.-H.; Tsai C.-H.; Chen C.-L.; Yang H.-C.; Liu C.-H.; Chen H.-H.; Chen P.-J.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:30:56Z |
Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients
|
Cheng H.-R.; Yang H.-C.; Lin S.-R.; Yang T.-Y.; Lin Y.-Y.; Su T.-H.; Tseng T.-C.; CHUN-JEN LIU; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:30:56Z |
Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconverters
|
Lin S.-R.; Yang T.-Y.; Peng C.-Y.; Lin Y.-Y.; Dai C.-Y.; Wang H.-Y.; Su T.-H.; Tseng T.-C.; Liu I.-J.; Cheng H.-R.; Shen Y.-C.; Wu F.-Y.; CHUN-JEN LIU; Chen D.-S.; Chen P.-J.; Yang H.-C.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:30:56Z |
Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapy
|
Liu C.-H.; Sun H.-Y.; Hsieh S.-M.; Liu W.-C.; Sheng W.-H.; CHUN-JEN LIU; Su T.-H.; Tseng T.-C.; Chen P.-J.; Hung C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:30:52Z |
Correction to: Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients (Hepatology International, (2021), 15, 3, (582-592), 10.1007/s12072-021-10186-7)
|
Cheng H.-R.; Yang H.-C.; Lin S.-R.; Yang T.-Y.; Lin Y.-Y.; Su T.-H.; Tseng T.-C.; CHUN-JEN LIU; Kao J.-H. |
| 臺大學術典藏 |
2021-12-01T02:29:06Z |
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan
|
Liu C.-H.; Liu C.-J.; CHIEN-CHING HUNG; Hsieh S.-M.; Su T.-H.; Sun H.-Y.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-09-27T05:32:39Z |
Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapy
|
Liu C.-H.; Sun H.-Y.; Hsieh S.-M.; Liu W.-C.; WANG-HUEI SHENG; Liu C.-J.; Su T.-H.; Tseng T.-C.; Chen P.-J.; Hung C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2021-09-04T06:18:52Z |
Subgenotypes of hepatitis B virus genotype C do not correlate with disease progression of chronic hepatitis B in Taiwan
|
Tseng T.-C.; Liu C.-J.; Chen P.-J.; Lai M.-Y.; Lin C.-L.; JIA-HORNG KAO; Chen D.-S. |
| 臺大學術典藏 |
2021-09-04T06:12:39Z |
Sequential combination therapy for chronic hepatitis B: More challenges to be tackled [7]
|
Tseng T.-C.; Liu C.-J.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:33Z |
A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients
|
Tseng T.-C.; Liu C.-J.; Wang C.-C.; Chen P.-J.; Lai M.-Y.; JIA-HORNG KAO; Chen D.-S. |
| 臺大學術典藏 |
2021-09-04T06:12:31Z |
Pegylated interferon-α-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: A multicenter, randomized controlled trial
|
Liu C.-H.; Liu C.-J.; Lin C.-.; Liang C.-C.; Hsu S.-J.; Yang S.-S.; Hsu C.-S.; Tseng T.-C.; Wang C.-C.; Lai M.-Y.; Chen J.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:29Z |
Elevation of serum aminotransferase activity increases risk of carotid atherosclerosis in patients with non-alcoholic fatty liver disease
|
Wang C.-C.; Lin S.-K.; Tseng Y.-F.; Hsu C.-S.; Tseng T.-C.; Lin H.H.; Wang L.-Y.; JIA-HORNG KAO |
